21 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/inxmed-fak-inhibitor-ifebemtinib-received-breakthrough-therapy-designation-by-china-national-medical-products-administration-for-first-line-non-small-cell-lung-cancer-nsclc-with-kras-g12c-mutation-302312546.html
LOOKING FOR A SUPPLIER?